Canine Atopic Dermatitis Market is Expected to Rake in Revenues Worth US$ 1666 Million by 2027-End

The global canine atopic dermatitis market size was estimated at USD 1005.90 million in 2020 and is expected to reach USD 1666 million and witness a CAGR of 9.0% during the forecast period. Increasing incidences of atopic dermatitis in dogs fuelled by air pollution and allergens is the key driver for this market. The most common symptoms associated with atopic dermatitis are scratching, itching, foul odour, loss of hair, scaly skin, etc. The breeds found to be most susceptible to this canine atopic dermatitis are Golden Retriever, German shepherd, Labrador, and Pug. Rapid industrialization in the developing and developed countries is anticipated to further propel the market growth.

Get PDF sample Copy –

https://www.envisageresearch.com/sample/EMR100417/

According to the American College of Veterinary Dermatology (ACVD) report, around 10% to 15% of dogs suffered from this canine atopic dermatitis in 2017. The x of this disease is not completely understood yet, though genetic abnormalities are reported to be one of the major reasons behind it. According to a study by the American Journal of Veterinary Research, the risk to develop canine atopic dermatitis in golden retrievers was around 50% in the U.K. due to geographic variation, which is expected to bolster the revenue in the coming years.

The increasing number of veterinary practitioners is one of the major factors driving the demand for this market. According to the American Veterinary Medical Association, a total of 113,394 veterinary practitioners were present in the U.S. in 2018 compared to 110,531 in 2017. Moreover, increasing number of veterinary hospitals and clinics is propelling the market growth.

Furthermore, increasing R&D investment by the key industry players, product launches, and strong drug pipeline are also expected to contribute significantly to the market growth. For instance, Kindred Biosciences, Inc. reportedly has 4 monoclonal antibodies in their pipeline for canine atopic dermatitis, which is expected to launch in the coming five years. In 2016, Zoetis launched Cytopoint, a monoclonal antibody which became a blockbuster drug in 2018.

The rising demand for pet insurance and increasing concern among pet owners are anticipated to exhibit a positive impact on the market in the coming years. Moreover, stringent regulations by the Food and Drug Administration (FDA) and other regulatory bodies in order to reduce the off-label usage of human drugs in animals is boosting the market growth. Key players in the market include Elanco, Virbac, and Toray Industries.

Analyst Commentary

On the basis of product, the canine atopic dermatitis treatment market is segmented into glucocorticoids, antihistamines, immunosuppressants, MAbs, and others. Glucocorticoids dominated the market in terms of revenue in 2020, owing to its increased usage and cheaper cost. Topical and oral glucocorticoids were found to be the first line of treatment for the management of canine atopic dermatitis. Oral prednisone, prednisolone, and methylprednisolone are usually preferred for the treatment of acute flares. The side effects are also minimal as compared to other dosage forms.
The Monoclonal Antibodies (MAbs) segment is expected to show lucrative growth over the forecast period. This treatment therapy is comparatively new and found to be very effective. Zoetis launched its first MAb in 2016, which is administered to the patients every four to eight weeks and is claimed to reduce itching immediately. There are more MAbs currently under clinical trials and are expected to show positive results in the coming years.

On the basis of mode of administration, the canine atopic dermatitis market is segmented into oral, topical, and injectable. The oral segment held the largest revenue share in 2020 owing to its lesser price. Moreover, it is more convenient as compared to injectable and topical modes. The dog owners can administer the drugs by themselves which is further fueling its demand.

The injectable segment is expected to show lucrative growth over the forecast period owing to its efficacy and potency. Rapid onset of action can be seen in the case of injectable, which is expected to propel the demand in the near future. Currently, veterinarians are prescribing a combination of oral and injectable therapy for better results. Growth of the injectable segment will be fuelled by the presence of an extensive product pipeline.

On the basis of mode of administration, the canine atopic dermatitis market is segmented into oral, topical, and injectable. The oral segment held the largest revenue share in 2020 owing to its lesser price. Moreover, it is more convenient as compared to injectable and topical modes. The dog owners can administer the drugs by themselves which is further fuelling its demand.

The injectable segment is expected to show lucrative growth over the forecast period owing to its efficacy and potency. Rapid onset of action can be seen in the case of injectable, which is expected to propel the demand in the near future. Currently, veterinarians are prescribing a combination of oral and injectable therapy for better results. Growth of the injectable segment will be fuelled by the presence of an extensive product pipeline.

By the distribution channel, the canine atopic dermatitis treatment market is segmented into veterinary hospitals/clinics, retail, and e-commerce. The retail segment dominated the market in 2020 owing to increased product availability. The advent of retail pharmacy chains is a major contributor to the share of the distribution channel segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in the prescriptions is anticipated to propel the revenue growth over the coming years. Moreover, veterinarians have begun to rely on general pharmacies to fill prescriptions for drugs, which are not available in vet pharmacies, which is further propelling the market growth.

By the distribution channel, the canine atopic dermatitis treatment market is segmented into veterinary hospitals/clinics, retail, and e-commerce. The retail segment dominated the market in 2020 owing to increased product availability. The advent of retail pharmacy chains is a major contributor to the share of the distribution channel segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in the prescriptions is anticipated to propel the revenue growth over the coming years. Moreover, veterinarians have begun to rely on general pharmacies to fill prescriptions for drugs, which are not available in vet pharmacies, which is further propelling the market growth.

Segmentation

The Canine Atopic Dermatitis Market is segmented on the basis of product, mode of administration, distribution channel, and region. On the basis of Product, the global market is segmented into Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others. On the basis of mode of administration, the global market is bifurcated into Topical, Oral, Injectable. On the basis of distribution channel Veterinary Hospitals/Clinics, Retail, E-commerce.

Regional Analysis

North America dominated the regional market in 2020 and is anticipated to witness the same trend over the forecast period. This growth can be attributed to the increasing incidence of canine atopic dermatitis in pet dogs, new product launches, and growing concern among pet owners. The rising pet ownership is further boosting the market growth. Furthermore, there is high investment in the development of new drugs by major players, which is expected to propel the growth over the forecast period.

Latin America held a substantial share owing to the presence of a large number of pet dogs in this region. Brazil and Argentina are among the top 10 countries having the highest number of pets in the world. Asia Pacific region is expected to show lucrative growth over the forecast period. The growing disposable income increases the probability of higher adoption of companion animals, which is further expanding the future growth prospects. Continual up-gradation of healthcare infrastructure is also presumed to present the market with high potential growth opportunities over the forecast period.

 

Buy this Report –

https://www.envisageresearch.com/buy/EMR100417/

About Us:

Envisage Market Research is the leading provider of custom and syndicated market research reports. Our team of expert analysts offers end-to-end consulting services, along with 80% of the Fortune 500+ companies in the recent past. We are focused to deliver market research report solutions to small and medium enterprises.

Envisage Market Research has steadily grown to become a trusted market research partner for clients across the globe. We are majorly focused to serve a wide range of industrial insights, including automotive & transportation, technology, consumer products, automation and equipment, food & beverages, services & utilities, chemicals & materials, energy, mining, and oil & gas.

Contact Us:

Envisage Market Research

Email: sales@envisageresearch.com

Back to top button